pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·May 12·1 min read
save

What I learned at a journalism fellowship about covering healthcare AI

Last week, I was reminded that reporting on AI in healthcare requires continuous scrutiny of the incentives that drive it. Thanks to a fellowship hosted by SABEW, in partnership with ...

May 12, 2026·read at Endpoints ↗

May 12, 2026 12:39 PM EDT Health Tech What I learned at a jour­nal­ism fel­low­ship about cov­er­ing health­care AI Ngai Yeung Health Tech Reporter Last week, I was re­mind­ed that re­port­ing on AI in health­care re­quires con­tin­u­ous scruti­ny of the in­cen­tives that dri­ve it. Thanks to a Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
81 words · retrieved May 12
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 3h agoNovartis' drug delivery deal with Alteogen; More worker cuts at CellaresEndpoints
  • 3h agoPfizer shares ADC rights with Medicus; RevMed updates lung cancer dataEndpoints
  • 4h agoAbbVie claims Phase 3 win for multiple myeloma drug etentamigEndpoints
  • 5h agoHealth tech investors are looking at bigger betsEndpoints
  • 7h agoSummit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trialEndpoints